Beam Therapeutics Inc. (BEAM) vs CRISPR Therapeutics AG (CRSP)
A side-by-side comparison of Beam Therapeutics Inc. and CRISPR Therapeutics AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
BEAM
Beam Therapeutics Inc.
$24.50HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
CRSP
CRISPR Therapeutics AG
$55.43HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — BEAM vs CRSP
growth of $100 · dividends reinvested · last 7yBEAM +30.1% (+3.8%/yr)CRSP +1.1% (+0.2%/yr)BEAM compounded faster over this window
BEAM CRSP
BEAM vs CRSP: by the numbers
- •CRSP is the larger company ($5.35B vs $2.52B market cap).
- •Both run net losses; BEAM's is the smaller (-54.75% vs -3368.72% net margin).
- •BEAM grew revenue faster over the past five years (479.04% vs 37.32% CAGR).
Metrics side by side
Valuation
| Metric | BEAM | CRSP |
|---|---|---|
| P/S ratio | 16.15 | 399.21 |
| P/B ratio | 2.36 | 3.06 |
Profitability
| Metric | BEAM | CRSP |
|---|---|---|
| Gross margin | 84.05% | -6537.01% |
| Operating margin | -274.57% | -16191.40% |
| Net margin | -54.75% | -3368.72% |
| ROE | -8.00% | -25.83% |
| ROIC | -28.96% | -21.12% |
Growth (annualized)
| Metric | BEAM | CRSP |
|---|---|---|
| Revenue CAGR (5Y) | 479.04% | 37.32% |
| Total return CAGR (5Y) | -22.35% | -13.01% |
Frequently asked
- Which has grown faster, BEAM or CRSP?
- Over the past five years, BEAM grew revenue faster — BEAM at a 479.04% CAGR versus CRSP at 37.32%.
- How have BEAM and CRSP total returns compared?
- Over the past 5 years, BEAM delivered -22.35% and CRSP delivered -13.01% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Beam Therapeutics ROECRISPR Therapeutics AG ROEBeam Therapeutics operating marginCRISPR Therapeutics AG operating marginBeam Therapeutics revenue growthCRISPR Therapeutics AG revenue growthBeam Therapeutics free cash flowCRISPR Therapeutics AG free cash flow
Beam Therapeutics & CRISPR Therapeutics AG appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.